VYGR Stock Analysis: Buy, Sell, or Hold?
VYGR - Voyager Therapeutics, Inc. Common Stock
$3.58
-0.19 (-5.05%)
▼
5d:
-13.23%
30d:
-13.44%
90d:
+4.84%
HOLD
MODERATE Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Get Alerted When VYGR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: VYGR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: VYGR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: VYGR is currently trading at $3.58, which is considered oversold relative to its 30-day fair value range of $3.77 to $4.13.
Technical Outlook: Technically, VYGR is showing support break momentum. The price is currently testing key support at $3.58. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.0% recently.
Market Sentiment: VYGR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $14.89 (+295.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, VYGR is showing support break momentum. The price is currently testing key support at $3.58. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.0% recently.
Market Sentiment: VYGR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $14.89 (+295.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.77 -
$4.13
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.0%)
- BULLISH: Trading 295.5% below Wall St target ($14.89)
- CAUTION: 5-day price weakness (-13.2%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$3.77 -
$4.13
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.59
Resistance Level
$4.46
Current Trend
Support Break
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.43
Wall Street Target
$14.89
(+295.5%)
Revenue Growth (YoY)
-59.9%
Share & Embed Analysis
Last updated: May 18, 2026 1:51 PM ET
Data refreshes hourly during market hours. Next update: 2:51 PM
Data refreshes hourly during market hours. Next update: 2:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VYGR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Alfred Sandrock
SELL
11511 shares
2026-04-02
Alfred Sandrock
SELL
14197 shares
2026-02-24
Nathan D Jorgensen
SELL
4668 shares
2026-02-24
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 58 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 61 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 56 HOLD |
